Vaxart, Inc. Share Price & Technical Analysis
VXRT · $0.64 (-5.88%)
Healthcare / Biotechnology
$0.64
-5.88%
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phase…
Price chart
Seasonality
May has 3 positive and 1 negative years (last 5 years shown)
-25% return in May, 21% avg return in past 3 year May month.
117% return in 2026, 8% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 100% | 33% | -25% | 33% | -25% | – | – | – | – | – | – | – | 117% |
| 25 | 0% | -17% | -20% | 0% | 0% | 0% | -20% | 0% | 33% | -25% | 33% | -25% | -40% |
| 24 | 100% | 0% | 8% | -46% | 14% | -12% | 0% | 29% | 0% | -11% | -25% | 17% | 73% |
| 23 | 10% | -27% | 0% | 0% | 50% | -42% | 14% | 0% | 0% | 0% | 0% | -14% | -9% |
| 22 | -22% | 4% | -2% | -31% | 3% | -5% | 6% | -14% | -27% | -23% | -29% | -17% | -158% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$159.10M
P/E ratio
4.11
52W high
$0.84
52W low
$0.26
Volume
1,88,222
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Vaxart, Inc. share price today?
- Vaxart, Inc. (VXRT) last traded around $0.64 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does VXRT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for VXRT. Download the app for real-time alerts.
- How can I analyze Vaxart, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.